

**AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1-39. (cancelled)

40. (Currently Amended) A composition for treating inflammatory components of a hormonally-dependent cancer, comprising a sulfated proteoglycan, one or more flavonoid compounds, an isoflavonoid compound and olive kernel extract.

41. (Previously Presented) The composition of claim 40, further comprising a chemotherapeutic agent.

42. (Previously Presented) The composition of claim 41, wherein said proteoglycan is chondroitin sulfate, said flavonoid compound is quercetin, said isoflavonoid compound is phenoxydiol, and said chemotherapeutic agent is tamoxifen or raloxifen.

43. (Currently Amended) The composition of claim 40, comprising, in mg/daymg, non-bovine chondroitin sulfate, 50-300; olive kernel extract, 150-600; quercetinquercetin, 500-1000; phenoxydiol isoflavone, 25-250; and genistein, 50-300.

44. (Currently Amended) The composition of claim 42, wherein said chemotherapeutic agent is 40 mg of tamoxifen or raloxifen is in the amount of 10 mg.

45. (Withdrawn) A method of treating the inflammatory components of a hormonally-dependent cancer, comprising the oral administration of a composition of claim 40.

46. (Withdrawn) A method of treating both the inflammatory components and the growth components of a hormonally-dependent cancer, comprising the administration of the composition of claim 42.

47. (Withdrawn) A method of treating the inflammatory components of a hormonally-dependent cancer, comprising the oral administration of a composition of claim 43.

48. (Withdrawn) A method of treating both the inflammatory components and the growth components of a hormonally-dependent cancer, comprising the administration of the composition of claim 44.

49. (Currently Amended) The composition of claim 40, wherein said cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, testicular cancer, prostrateprostate cancer, pituitary cancer, endometrial cancer, and melanoma.
50. (Previously Presented) The composition of claim 40, comprising therapeutically effective amounts of chondroitin sulfate, olive kernel extract, phenoxydiol isoflavone, quercetin, and genistein.
51. (Previously Presented) The composition of claim 50, wherein the chondroitin sulfate is non-bovine chondroitin sulfate.
52. (Previously Presented) The composition of claim 51, further comprising a therapeutically effective amount of tamoxifen or raloxifen
53. (New) A composition for treating hormonally-dependent cancer, comprising a sulfated proteoglycan, one or more flavonoid compounds, an isoflavonoid compound, olive kernel extract, and a chemotherapeutic agent.
54. (New) The composition of claim 53, wherein said proteoglycan is chondroitin sulfate, said flavonoid compound is quercetin, said isoflavonoid compound is phenoxydiol, and said chemotherapeutic agent is tamoxifen or raloxifen.
55. (New) The composition of claim 53, comprising, in mg, non-bovine chondroitin sulfate, 50-300; olive kernel extract, 150-600; quercetin, 500-1000; phenoxydiol isoflavone, 25-250; and genistein, 50-300.
56. (New) The composition of claim 54, wherein said tamoxifen or raloxifen is in the amount of 10 mg.
57. (New) The composition of claim 53, wherein said cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, testicular cancer, prostate cancer, pituitary cancer, endometrial cancer, and melanoma.
58. (New) The composition of claim 53, comprising therapeutically effective amounts of chondroitin sulfate, olive kernel extract, phenoxydiol isoflavone, quercetin, and genistein.
59. (New) The composition of claim 58, wherein the chondroitin sulfate is non-bovine chondroitin sulfate.

60. (New) The composition of claim 59, wherein the chemotherapeutic agent is a therapeutically effective amount of tamoxifen or raloxifen.